PARP Inhibitors in Age-related Macular Degeneration:

Control of angiogenesis has a broad spectrum of potential therapeutic applications, ranging from treatment of cancer to age-related macular degeneration. In an in vitro model of angiogenesis, treatment with an Inotek PARP inhibitor blocked angiogenesis inhibiting new blood vessel formation (Pyriochou et al., Int J Mol Med 2008). Currently, Inotek is conducting preclinical studies to assess the therapeutic potential of PARP inhibitors in the treatment of AMD.